3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Transitional Cell
7
Urinary Bladder Neoplasms
5
Urologic Neoplasms
2
Peripheral Nervous System Diseases
2
Neoplasm Metastasis
2
Urothelial Cancer
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Ureteral Neoplasms
1
Penile Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Muscle-invasive Bladder Cancer
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Male Urogenital Diseases
1
Female Urogenital Diseases
1
Advanced Bladder Cancer
1
Adenocarcinoma of the Bladder
1
Interventions
Bevacizumab
26
Cetuximab
24
Fluorouracil
23
Leucovorin
22
Oxaliplatin
19
pembrolizumab
18
Specimen Handling
11
Irinotecan
10
Nivolumab
8
Magnetic Resonance Spectroscopy
8
atezolizumab
7
Biopsy
7
Pemetrexed
6
Panitumumab
6
Cisplatin
6
Carboplatin
6
trifluridine tipiracil drug combination
5
fludarabine
5
encorafenib
5
HMPL-013
5
Gemcitabine
5
Folfox protocol
5
Standard of Care
4
Immunoglobulin G
4
Disulfides
4
Cyclophosphamide
4
zanidatamab
3
regorafenib
3
fludarabine phosphate
3
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
enfortumab vedotin
×
30 days
×
Clear all
No trials found.